Dr. Marwan G. Fakih discussed the FDA approval of Lumakras with Vectibix for third-line treatment of KRAS G12C-mutated ...
Research co-led by University of Toronto researchers and Insilico Medicine has demonstrated the potential of quantum ...
CAYMAN ISLANDS - Silexion Therapeutics Corp. (NASDAQ: SLXN), a biotech firm focusing on RNA interference (RNAi) treatments, ...
On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...
Precision medicines biotech Frontier Medicines is leaving behind an unknown number of staffers as it refocuses resources to ...
Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations ...
A new study from Moffitt Cancer Center could help doctors predict how well patients with a specific type of lung cancer will ...
Revolution Medicines' promising KRAS inhibitors show potential in pancreatic cancer. See why we recommend a hold rating on ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
SIL-204 administered in an extended release formulation reduced tumor growth by ~50% after 30 days, with ~50% of tumors showing complete necrosis, in human pancreatic tumors harboring a G12D mutation ...
Alexander I. Spira, MD, PhD, FACP, discusses the clinical implications of ctDNA for treatment decisions and monitoring in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback